126 related articles for article (PubMed ID: 37580675)
21. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.
Lee N; Fawaaz R; Olsson CA; Benson MC; Petrylak DP; Schiff PB; Bagiella E; Singh A; Ennis RD
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1443-6. PubMed ID: 11121646
[TBL] [Abstract][Full Text] [Related]
22. Geospatial analysis, web-based mapping and determinants of prostate cancer incidence in Georgia counties: evidence from the 2012-2016 SEER data.
Aheto JMK; Utuama OA; Dagne GA
BMC Cancer; 2021 May; 21(1):508. PubMed ID: 33957887
[TBL] [Abstract][Full Text] [Related]
23. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
[TBL] [Abstract][Full Text] [Related]
24. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
Kuban D; Thames H; Levy L; Horwitz E; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):409-14. PubMed ID: 15667960
[TBL] [Abstract][Full Text] [Related]
25. Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
Wang M; Wasserman E; Geyer N; Carroll RM; Zhao S; Zhang L; Hohl R; Lengerich EJ; McDonald AC
BMC Cancer; 2020 May; 20(1):394. PubMed ID: 32375682
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men.
Yarney J; Vanderpuye V; Mensah J
Urol Oncol; 2013 Apr; 31(3):325-30. PubMed ID: 21441045
[TBL] [Abstract][Full Text] [Related]
27. PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions.
Deuker M; Stolzenbach LF; Pecoraro A; Rosiello G; Luzzago S; Tian Z; Saad F; Chun FK; Karakiewicz PI
World J Urol; 2021 Mar; 39(3):787-796. PubMed ID: 32458094
[TBL] [Abstract][Full Text] [Related]
28. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
29. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer.
Bratt O; Folkvaljon Y; Loeb S; Klotz L; Egevad L; Stattin P
BJU Int; 2015 Aug; 116(2):213-9. PubMed ID: 25053197
[TBL] [Abstract][Full Text] [Related]
30. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
31. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy.
Ennis RD; Malyszko BK; Heitjan DF; Rubin MA; O'Toole KM; Schiff PB
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):511-7. PubMed ID: 9635696
[TBL] [Abstract][Full Text] [Related]
32. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract][Full Text] [Related]
33. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
35. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
36. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
Critz FA
J Urol; 2002 Mar; 167(3):1310-3. PubMed ID: 11832720
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
39. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
40. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
